Work

A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.3077

Authors: Thatcher Ross Heumann, Shannon Stockton, Michael Cecchini, Raid Aljumaily, Cathy Shyr, Jennifer Whisenant, Jason S. Starr, Farshid Dayyani, Joaquina Celebre Baranda, Nikolaos Trikalinos, S. Percy Ivy, Patricia LoRusso, Satya Das, Steven Gore, Jan Hendrik Beumer, Jordan Berlin

Institutions: Vanderbilt University, Vanderbilt-Ingram Cancer Center, Yale Cancer Center, Yale University, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Vanderbilt University Medical Center, Mayo Clinic in Florida, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, University of Kansas, The University of Kansas Cancer Center, Washington University in St. Louis, National Cancer Institute, UPMC Hillman Cancer Center

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399737490

Cites:

Cited by: 4

Related to: 10